Free tool
FAERS Monitor: Oxytrol
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021351 or its brand name (Oxytrol, Oxybutynin). Reports on generic versions are filed under their own applications.
Reports
23,120
Serious
13,881
60% of reports
Hospitalization
6,938
Death reported
1,707
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective1,792
- fatigue1,543
- fall1,497
- nausea1,185
- diarrhoea1,075
- urinary tract infection1,053
- dizziness1,039
- pain1,012
- headache949
- off label use930
- asthenia903
- dyspnoea757
- gait disturbance725
- constipation707
- death706
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 203 |
| 2005 | 250 |
| 2006 | 188 |
| 2007 | 73 |
| 2008 | 80 |
| 2009 | 123 |
| 2010 | 370 |
| 2011 | 595 |
| 2012 | 739 |
| 2013 | 746 |
| 2014 | 1,222 |
| 2015 | 1,549 |
| 2016 | 1,829 |
| 2017 | 1,897 |
| 2018 | 2,032 |
| 2019 | 2,072 |
| 2020 | 1,786 |
| 2021 | 1,489 |
| 2022 | 1,470 |
| 2023 | 1,370 |
| 2024 | 1,014 |
| 2025 | 1,179 |
| 2026 | 843 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,031,039 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| urinary tract infectionSignal | 1,053 | 5.6 | 5.3 | 4,028 |
| fallSignal | 1,497 | 4.1 | 3.9 | 3,554 |
| gait disturbanceSignal | 725 | 3.5 | 3.2 | 1,269 |
| constipationSignal | 707 | 3.0 | 2.7 | 919 |
| astheniaSignal | 903 | 2.2 | 2.1 | 590 |
| dizziness | 1,039 | 1.9 | 1.8 | 449 |
| fatigue | 1,543 | 1.8 | 1.7 | 573 |
| diarrhoea | 1,075 | 1.5 | 1.4 | 194 |
| pain | 1,012 | 1.5 | 1.4 | 173 |
| headache | 949 | 1.4 | 1.3 | 101 |
| nausea | 1,185 | 1.4 | 1.3 | 118 |
| drug ineffective | 1,792 | 1.2 | 1.2 | 87 |
| dyspnoea | 757 | 1.2 | 1.1 | 30 |
| off label use | 930 | 1.0 | 0.9 | 1 |
| death | 706 | 0.7 | 0.7 | 64 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.